Tags

Type your tag names separated by a space and hit enter

Inhibition of analgesic-induced asthma by leukotriene receptor antagonist ONO-1078.
Am J Respir Crit Care Med. 1994 Jul; 150(1):254-7.AJ

Abstract

We evaluated the effect of ONO-1078, a selective leukotriene-C4, -D4, and -E4-receptor antagonist, on bronchoconstriction intensity during inhalation challenge with dipyrone (a pyrazolone derivative) in six aspirin-sensitive asthmatics. A double-blind, randomized, crossover design was used. After ingestion of 225 mg ONO-1078 or matching placebo, subjects underwent bronchial provocation with dipyrone on two occasions, separated by 4 wk. Aerosol inhalation of dipyrone was performed increasing the concentration stepwise from 0.08 to 10% (wt/vol). FEV1 was measured every 10 min up to 30 min after inhalation of each concentration. Threshold concentrations causing a fall in FEV1 > or = 20% of baseline value were 0.4% in four subjects and 2% in the other two on the placebo day. After pretreatment with ONO-1078, threshold concentration was 10% in two subjects, and no fall in FEV1 was observed in the other four, even after inhalation of 10% dipyrone. Values of PD20 were 21.9 +/- 8.2 units (mean +/- SEM) after placebo and 311.6 +/- 40.3 units after ONO-1078, respectively, and a statistically significant difference occurred (p < 0.001). Provocation of bronchoconstriction was completely inhibited in subjects whose plasma ONO-1078 levels were more than 0.5 microgram/ml. These results support the hypothesis that sulfidopeptide leukotriene-induced bronchoconstriction is one important component in the pathophysiology of aspirin-induced asthma.

Authors+Show Affiliations

Second Department of Internal Medicine, Saitama Medical School, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

8025759

Citation

Yamamoto, H, et al. "Inhibition of Analgesic-induced Asthma By Leukotriene Receptor Antagonist ONO-1078." American Journal of Respiratory and Critical Care Medicine, vol. 150, no. 1, 1994, pp. 254-7.
Yamamoto H, Nagata M, Kuramitsu K, et al. Inhibition of analgesic-induced asthma by leukotriene receptor antagonist ONO-1078. Am J Respir Crit Care Med. 1994;150(1):254-7.
Yamamoto, H., Nagata, M., Kuramitsu, K., Tabe, K., Kiuchi, H., Sakamoto, Y., Yamamoto, K., & Dohi, Y. (1994). Inhibition of analgesic-induced asthma by leukotriene receptor antagonist ONO-1078. American Journal of Respiratory and Critical Care Medicine, 150(1), 254-7.
Yamamoto H, et al. Inhibition of Analgesic-induced Asthma By Leukotriene Receptor Antagonist ONO-1078. Am J Respir Crit Care Med. 1994;150(1):254-7. PubMed PMID: 8025759.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Inhibition of analgesic-induced asthma by leukotriene receptor antagonist ONO-1078. AU - Yamamoto,H, AU - Nagata,M, AU - Kuramitsu,K, AU - Tabe,K, AU - Kiuchi,H, AU - Sakamoto,Y, AU - Yamamoto,K, AU - Dohi,Y, PY - 1994/7/1/pubmed PY - 1994/7/1/medline PY - 1994/7/1/entrez SP - 254 EP - 7 JF - American journal of respiratory and critical care medicine JO - Am. J. Respir. Crit. Care Med. VL - 150 IS - 1 N2 - We evaluated the effect of ONO-1078, a selective leukotriene-C4, -D4, and -E4-receptor antagonist, on bronchoconstriction intensity during inhalation challenge with dipyrone (a pyrazolone derivative) in six aspirin-sensitive asthmatics. A double-blind, randomized, crossover design was used. After ingestion of 225 mg ONO-1078 or matching placebo, subjects underwent bronchial provocation with dipyrone on two occasions, separated by 4 wk. Aerosol inhalation of dipyrone was performed increasing the concentration stepwise from 0.08 to 10% (wt/vol). FEV1 was measured every 10 min up to 30 min after inhalation of each concentration. Threshold concentrations causing a fall in FEV1 > or = 20% of baseline value were 0.4% in four subjects and 2% in the other two on the placebo day. After pretreatment with ONO-1078, threshold concentration was 10% in two subjects, and no fall in FEV1 was observed in the other four, even after inhalation of 10% dipyrone. Values of PD20 were 21.9 +/- 8.2 units (mean +/- SEM) after placebo and 311.6 +/- 40.3 units after ONO-1078, respectively, and a statistically significant difference occurred (p < 0.001). Provocation of bronchoconstriction was completely inhibited in subjects whose plasma ONO-1078 levels were more than 0.5 microgram/ml. These results support the hypothesis that sulfidopeptide leukotriene-induced bronchoconstriction is one important component in the pathophysiology of aspirin-induced asthma. SN - 1073-449X UR - https://www.unboundmedicine.com/medline/citation/8025759/Inhibition_of_analgesic_induced_asthma_by_leukotriene_receptor_antagonist_ONO_1078_ L2 - http://www.atsjournals.org/doi/full/10.1164/ajrccm.150.1.8025759?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -